|
Phase I trial evaluating safety and efficacy of intratumorally administered allogeneic monocyte-derived cells (ilixadencel) in advanced gastrointestinal stromal tumors. |
|
|
|
|
Stock and Other Ownership Interests - Immunicum |
Consulting or Advisory Role - Immunicum |
Travel, Accommodations, Expenses - Immunicum |
|
|
No Relationships to Disclose |
|
|
Employment - ITBMed; ITBMed (I) |
Leadership - ITBMed; ITBMed (I) |
Stock and Other Ownership Interests - ITBMed; ITBMed (I) |
Patents, Royalties, Other Intellectual Property - ITBMed; ITBMed (I) |
|
|
Employment - ITBMed; ITBMed (I) |
Leadership - ITBMed; ITBMed (I) |
Stock and Other Ownership Interests - ITBMed; ITBMed (I) |
Patents, Royalties, Other Intellectual Property - ITBMed; ITBMed (I) |
|
|
No Relationships to Disclose |
|
Christina Linder-Stragliotto |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |